Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders

Core Viewpoint - Harmony Biosciences Holdings, Inc. has announced a public offering of up to 8,000,000 shares of its common stock, with no proceeds going to the company itself [1] Group 1: Offering Details - The public offering is being conducted by Marshman Fund Trust II and Valor IV Pharma Holdings, LLC as the selling shareholders [1] - The selling shareholders plan to grant underwriters a 30-day option to purchase an additional 1,200,000 shares at the public offering price [1] - J.P. Morgan is acting as the sole book-running manager for the offering [2] Group 2: Regulatory Information - The shares are being offered under an effective shelf registration statement filed with the SEC, and the offering will be made via a prospectus supplement and accompanying base prospectus [3] - Copies of the preliminary prospectus supplement and base prospectus can be obtained for free on the SEC's website or through J.P. Morgan Securities LLC [3] Group 3: Company Overview - Harmony Biosciences is a pharmaceutical company focused on developing therapies for patients with rare neurological diseases [5] - The company was established in 2017 by Paragon Biosciences, LLC, and is headquartered in Plymouth Meeting, Pennsylvania [5] - The company's mission emphasizes innovation and empathy to improve the lives of patients with unmet medical needs [5]